Combined Screening with Haemoglobinopathies- Roche (SSDW)

1. Free Beta HCG (1)
   1. Free Beta HCG
2. Hemoglobin Variant Analysis (HB HPLC) (15)
   1. Foetal Haemoglobin (HbF)
   2. Haemoglobin A0 (HB A0)
   3. Haemoglobin A2 (HbA2)
   4. Haemoglobin C (HbC)
   5. Haemoglobin D (HbD)
   6. Haemoglobin E (HbE)
   7. Haemoglobin S (HbS)
   8. Hemoglobin Hb
   9. MCH
   10. MCHC
   11. MCV
   12. PCV Haematocrit
   13. RBC Count
   14. RDW-CV
   15. RDW-SD
3. Pregnancy Associated Plasma Protein-A (PAPP-A) (1)
   1. Pregnancy Associated Plasma Protein-A (PAPP-A)

Combined Screening with Haemoglobinopathies (SSDW) is a specialized prenatal screening test used to detect common genetic disorders, including thalassemia and sickle cell disease, in the fetus during pregnancy.

The “SSDW” in the test name likely refers to the following components:

S: Sickle Cell Disease (hemoglobin S)
S: Beta-thalassemia (hemoglobin S)
D: Delta-thalassemia (hemoglobin D)
W: Other Hemoglobin Variants (hemoglobin W, which stands for other uncommon hemoglobin variants)

The test combines different screening methods, including hemoglobin electrophoresis and molecular genetic techniques, to identify abnormal hemoglobin variants associated with hemoglobinopathies.

Hemoglobinopathies are a group of inherited blood disorders caused by mutations in the genes that produce hemoglobin, the protein responsible for carrying oxygen in red blood cells. Common hemoglobinopathies include sickle cell disease and various types of thalassemia.

During the Combined Screening with Haemoglobinopathies (SSDW) test, healthcare providers analyze a sample of the mother’s blood to detect abnormal hemoglobin variants that may indicate the presence of hemoglobinopathies in the fetus.

This screening is especially crucial in populations where thalassemia and sickle cell disease are prevalent. Early detection of these conditions allows for proper medical management and the possibility of providing appropriate care to the baby once born.